Titan Medical Inc. Appoints Dr. John R. Valvo as Vice President of Medical Affairs
TORONTO, ONTARIO -- (MARKET WIRE) -- 07/07/11 -- Titan Medical Inc. ("the Company") (TSX VENTURE: TMD) today announced that it has appointed Dr. John R. Valvo, M.D., F.A.C.S. as Vice President of Medical Affairs, effective immediately. He will be reporting directly to Craig Leon, Chief Executive Officer of Titan Medical.
"Dr. Valvo joins Titan Medical at a vital point in our Company's stage of development," said Mr. Leon. "His wealth of knowledge and expertise in robotic surgery will be an important asset in building a novel robotic surgical platform, leading our world-class medical affairs team, and supporting the clinical launch and commercialization of Amadeus. Since his appointment to our medical advisory board nearly a year ago, he has provided innovative thought and leadership, and I am pleased to welcome him to the Titan Medical management team."
"I look forward to working as an integral member of the Titan core team, preparing Amadeus for scientific and clinical trials, future commercialisation, and helping to expand Titan Medical's portfolio," commented Dr. Valvo.
Dr. Valvo is currently the Chief of Urology and Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic program at Rochester General Hospital in early 2004, which currently ranks in the top four percent of robotic surgeries in the United States with over 30 robotic surgeons and over 4,000 robotic surgeries performed to date. Having authored more than 100 scientific articles and helped to create many robotic programs in the northeast, Dr. Valvo's focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery, which has become a template for many upstart robotic surgery programs throughout the country. Additionally, he has experience performing complex urologic surgery for cancers of the genitourinary tract through the surgical platform. He is a fellow of the American College of Surgeons and American Urological Association and is certified by the American Board of Urology. He is also a member of the Monroe County Medical Society, the Minimally Invasive Robotic Association and the Society for Lap Endoscopic Surgeons. Dr. Valvo earned his bachelor of science at Marietta College and his M.D. from SUNY Buffalo.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus™, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The current global robotic surgical market size is approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 31, 2011 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer (416) 548-7522 (ext. 151) cleon@titanmedicalinc.com www.titanmedicalinc.com Sherry Bertner Managing Director ICR, LLC (646) 277-1247 Sherry.Bertner@icrinc.com
Source: Titan Medical Inc.
Released July 7, 2011